The additional share purchase rights (02675) of EDGE MEDICAL-B have been exercised, marking the end of the stable price period.
Jingfeng Medical-B (02675) announced that the overall coordinator (for itself and on behalf of the international underwriters) has fully exercised the additional share subscription rights stipulated in the prospectus on February 4, 2026 (Wednesday), involving a total of 4.1583 million H shares, accounting for approximately 15% of the total number of shares available for subscription under the global offering (before any exercise of additional share subscription rights). The additional shares will be issued and distributed by the company at a price of HK$43.24 per H share. The additional shares will be used to expedite the delivery of certain H shares to subscribers who have agreed to delay the delivery of their subscribed H shares under the global offering.
EDGE MEDICAL-B (02675) announced that the overall coordinator (for itself and on behalf of international underwriters) has fully exercised the oversubscription rights as stated in the prospectus on February 4, 2026 (Wednesday), involving a total of 4.1583 million H shares, representing approximately 15% of the total number of shares available for subscription under the global offering (before any oversubscription rights were exercised). The oversubscribed shares will be issued and distributed by the company at a price of HK$43.24 per H share. The oversubscribed shares will be used to expedite the delivery of a portion of H shares to subscribers who have agreed to purchase H shares under the global offering but experienced delayed delivery.
The stabilizing period for the global offering ended on February 4, 2026 (Wednesday) (i.e., 30 days after the deadline for submitting the Hong Kong public offering application). The stabilizing actions carried out by the stabilization operator, Morgan Stanley Asia Limited or its affiliates or any person acting on their behalf during the stabilizing period are listed below:
(1) Oversubscription of a total of 4.1583 million H shares in the international offering, representing approximately 15% of the total number of shares available for subscription under the global offering (before any oversubscription rights were exercised); and
(2) The overall coordinator (for itself and on behalf of international underwriters) fully exercised the oversubscription rights for a total of 4.1583 million H shares at HK$43.24 per H share on February 4, 2026 (Wednesday) to expedite the delivery of a portion of H shares to subscribers who have agreed to purchase H shares under the global offering but experienced delayed delivery.
During the stabilizing period, the stabilization operator did not engage in any buying or selling of H shares in the market for stabilization purposes.
Related Articles
QYUNS-B (02509) spent approximately HK$1.8714 million to repurchase 93,000 shares on February 4th.
US Stock Market Move | Raise Annual Revenue Expectations: Super Micro Computer, Inc. (SMCI.US) Surges Over 12% at Opening.
DEEWIN (02418) issued a profit warning. It is expected that the net profit for the year 2025 will be approximately 45 to 55 million yuan, a decrease of about 65% to 71% compared to the same period last year.
QYUNS-B (02509) spent approximately HK$1.8714 million to repurchase 93,000 shares on February 4th.
US Stock Market Move | Raise Annual Revenue Expectations: Super Micro Computer, Inc. (SMCI.US) Surges Over 12% at Opening.
DEEWIN (02418) issued a profit warning. It is expected that the net profit for the year 2025 will be approximately 45 to 55 million yuan, a decrease of about 65% to 71% compared to the same period last year.
RECOMMEND
Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026
Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026
2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026
